Fc γ receptors

Immunology Letters

Volumn 92, Issue 3, 2004, Pages 199-205

  Cohen Solal, Joël Fg ^a   Cassard, Lydie ^a   Fridman, Wolf Herman ^a   Sautès Fridman, Catherine ^a  

^a INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; BEVACIZUMAB; CYTOKINE; DACLIZUMAB; EDRECOLOMAB; FC RECEPTOR; GAMMA INTERFERON; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G ANTIBODY; MONOCLONAL ANTIBODY; PERTUZUMAB; RITUXIMAB; SEROTONIN; TRASTUZUMAB; UNCLASSIFIED DRUG;

ANAPHYLAXIS; ANTIGEN ANTIBODY COMPLEX; ANTIGEN PRESENTATION; ANTIGEN SPECIFICITY; AUTOIMMUNE DISEASE; AUTOIMMUNITY; B CELL LYMPHOMA; B LYMPHOCYTE; CELL ACTIVATION; CELL DIFFERENTIATION; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; COLORECTAL CANCER; CYTOKINE PRODUCTION; CYTOKINE RELEASE; CYTOPLASM; DENDRITIC CELL; GENE DELETION; GLOMERULONEPHRITIS; HUMAN; HUMORAL IMMUNITY; HYPERSENSITIVITY REACTION; IDIOPATHIC THROMBOCYTOPENIC PURPURA; LUNG ALVEOLITIS; MACROPHAGE; MAST CELL; MELANOMA; MONOCYTE; NATURAL KILLER CELL; NEUTROPHIL; NUDE MOUSE; PHAGOCYTOSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR BINDING; RECEPTOR DOWN REGULATION; REVIEW; TUMOR GROWTH;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; AUTOIMMUNITY; HUMANS; IMMUNOGLOBULIN G; NEOPLASMS; RECEPTORS, IGG;

EID: 1842815081     PISSN: 01652478     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.imlet.2004.01.012     Document Type: Review

References (55)

1. Ravetch J., Bolland S. IgG Fc receptors. Annu. Rev. Immunol. 19:2001;275-290.
2. Reth M. Antigen receptor tail clue. Nature. 338:1989;383-384.
3. Van den Herik-Oudijk I.E., Capel P.J., van der Bruggen T., Van de Winkel J.G. Identification of signaling motifs within human FcγRIIa and FcγRIIb isoforms. Blood. 85:1995;2202-2211.
4. Hulett M.D., Hogarth P.M. Molecular basis of Fc receptor function. Adv. Immunol. 57:1994;1-127.
5. Amigorena S., Bonnerot C., Drake J.R., Choquet D., Hunziker W., Guillet J.G.et al. Cytoplasmic domain heterogeneity and functions of IgG Fc receptors in B lymphocytes. Science. 256:1992;1808-1812.
6. Daeron M. Fc receptor biology. Annu. Rev. Immunol. 5:1997;203-234.
7. Pricop L., Redecha P., Teillaud J.L., Frey J., Fridman W.H., Sautes-Fridman C.et al. Differential modulation of stimulatory and inhibitory FcγR on human monocytes by Th1 and Th2 cytokines. J. Immunol. 166:2001;531-537.
8. Lanier L.L., Cwirla S., Yu G., Testi R., Phillips J.H. Membrane anchoring of a human IgG Fc receptor (CD16) determined by a single amino acid. Science. 246:1989;1611-1613.
9. Salmon J.E., Edberg J.C., Kimberly R.P. FcγRIII on human neutrophils. Allelic variants have functionally distinct capacities. J Clin Invest. 85:1990;1287-1295.
10. Boros P., Odin J.A., Muryoi T., Masur S.K., Bona C., Unkeless J.C. IgM anti-FcγR autoantibodies trigger neutrophil degranulation. J. Exp. Med. 173:1991;1473-1482.
11. Sautes C., Teillaud C., Mazieres N., Tartour E., Bouchard C., Galinha A.et al. Soluble FcγR (sFcγR): detection in biological fluids and production of a murine recombinant sFcγR biologically active in vitro and in vivo. Immunobiology. 185:1992;207-221.
12. Galon J., Gauchat J.F., Mazieres N., Spagnoli R., Storkus W., Lotze M.et al. Soluble FcγR (FcγRIII, CD16) triggers cell activation through interaction with complement receptors. J. Immunol. 157:1996;1184-1192.
13. Kato K., Sautes-Fridman C., Yamada W., Kobayashi K., Uchiyama S., Kim H.et al. Structural basis of the interaction between IgG and FcγR. J. Mol. Biol. 295:2000;213-224.
14. Radaev S., Motyka S., Fridman W.H., Sautes-Fridman C., Sun P.D. The structure of a human type III FcγR in complex with Fc. J. Biol. Chem. 276:2001;16469-16477.
15. Maxwell K.F., Powell M.S., Hulett M.D., Barton P.A., McKenzie I.F., Garrett T.P.et al. Crystal structure of the human leukocyte Fc receptor, FcγRIIa. Nat. Struct. Biol. 6:1999;437-442.
16. Sondermann P., Jacob U., Kutscher C., Frey J. Characterization and crystallization of soluble human FcγRII (CD32) isoforms produced in insect cells. Biochemistry. 29:1999;8469-8477.
17. Zhang Y., Boesen C.C., Radaev S., Brooks A.G., Fridman W.H., Sautes-Fridman C.et al. Crystal structure of the extracellular domain of a human FcγRIII. Immunity. 13:2000;387-395.
18. Sondermann P., Huber R., Oosthuizen V., Jacob U. The 3.2-A crystal structure of the human IgG1 Fc fragment-FcγRIII complex. Nature. 406:2000;267-273.
19. Radaev S., Sun P. Recognition of immunoglobulins by FcγR. Mol. Immunol. 38:2002;1073-1083.
20. Hazenbos W.L., Gessner J.E., Hofhuis F.M., Kuipers H., Meyer D., Heijnen I.A.et al. Verbeek JS.Impaired IgG-dependent anaphylaxis and Arthus reaction in FcγRIII (CD16) deficient mice. Immunity. 5:1996;181-188.
21. Barnes N., Gavin A.L., Tan P.S., Mottram P., Koentgen F., Hogarth P.M. FcγRI-deficient mice show multiple alterations to inflammatory and immune responses. Immunity. 16:2002;379-389.
22. Takai T., Li M., Sylvestre D., Clynes R., Ravetch J.V. FcR γ chain deletion results in pleiotrophic effector cell defects. Cell. 76:1994;519-529.
23. oan-Facsinay A., de Kimpe S.J., Hellwig S.M., van Lent P.L., Hofhuis F.M., van Ojik H.H.et al. FcγRI (CD64) contributes substantially to severity of arthritis, hypersensitivity responses, and protection from bacterial infection. Immunity. 16:2002;391-402.
24. Hazenbos W.L., Heijnen I.A., Meyer D., Hofhuis F.M., Renardel de Lavalette C.R., Schmidt R.E.et al. Murine IgG1 complexes trigger immune effector functions predominantly via Fc gamma RIII (CD16). J. Immunol. 161:1998;3026-3032.
25. Baumann U., Kohl J., Tschernig T., Schwerter-Strumpf K., Verbeek J.S., Schmidt R.E.et al. A codominant role of Fcγ RI/III and C5aR in the reverse Arthus reaction. J. Immunol. 164:2000;1065-1070.
26. Takai T., Ono M., Hikida M., Ohmori H., Ravetch J.V. Augmented humoral and anaphylactic responses in FcγRII-deficient mice. Nature. 379:1996;346-349.
27. Yuasa T., Kubo S., Yoshino T., Ujike A., Matsumura K., Ono M.et al. Deletion of FcγIIB renders H-2(b) mice susceptible to collagen-induced arthritis. J. Exp. Med. 189:1999;187-194.
28. Kleinau S., Martinsson P., Heyman B. Induction and suppression of collagen-induced arthritis is dependent on distinct FcγR. J. Exp. Med. 191:2000;1611-1616.
29. Schiller C., Janssen-Graalfs I., Baumann U., Schwerter-Strumpf K., Izui S., Takai T.et al. Mouse FcγRII is a negative regulator of FcγRIII in IgG immune complex-triggered inflammation but not in autoantibody-induced hemolysis. Eur. J. Immunol. 30:2000;481-490.
30. Bolland S., Ravetch J.V. Spontaneous autoimmune disease in FcγRIIB-deficient mice results from strain-specific epistasis. Immunity. 3:2000;277-285.
31. Van de Winkel J.G.J., Anderson C.L. Biology of human immunoglobulin G Fc receptors. J. Leukoc Biol. 49:1991;511-524.
32. Koene H.R., Kleijer M., Algra J., Roos D., von dem Borne A.E., de Haas M. FcγRIIIa-158V/F polymorphism influences the binding of IgG by natural killer cell FcγRIIIa, independently of the FcγRIIIa-48L/R/H phenotype. Blood. 90:1997;1109-1114.
33. White C.A., Weaver R.L., Grillo-Lopez A.J. Antibody-targeted immunotherapy for treatment of malignancy. Annu. Rev. Med. 52:2001;125-145.
34. Nguyen D.T., Amess J.A., Doughty H., Hendry L., Diamond L.W. IDEC-C2B8 anti-CD20 (rituximab) immunotherapy in patients with low-grade non-Hodgkin's lymphoma and lymphoproliferative disorders: evaluation of response on 48 patients. Eur. J. Haematol. 62:1999;76-82.
35. Goldenberg M.M. Trastuzumab, a recombinant DNA-derived humanized monoclonal antibody, a novel agent for the treatment of metastatic breast cancer. Clin. Ther. 21:1999;309-318.
36. Osterborg A., Dyer M.J., Bunjes D., Pangalis G.A., Bastion Y., Catovsky D.et al. Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. European Study Group of CAMPATH-1H Treatment in Chronic Lymphocytic Leukemia. J. Clin. Oncol. 15:1997;1567-1574.
37. Riethmuller G., Holz E., Schlimok G., Schmiegel W., Raab R., Hoffken K.et al. Monoclonal antibody therapy for resected Dukes' C colorectal cancer: seven-year outcome of a multicenter randomized trial. J. Clin. Oncol. 16:1998;1788-1794.
38. Cartron G., Dacheux L., Salles G., Solal-Celigny P., Bardos P., Colombat P.et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcγRIIIA gene. Blood. 99:2002;754-758.
39. Weng W.K., Levy R. Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J. Clin. Oncol. 21:2003;3940-3947.
40. Clynes R.A., Towers T.L., Presta L.G., Ravetch J.V. Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat Med. 6:2000;443-446.
41. Van Spriel A.B., Van Ojik H.H., Van de Winkel J.G.J. Immunotherapeutic perspective for bispecific antibodies. Immunol. Today. 21:2000;391-397.
42. Bayry J., Pashov A., Donkova V., Delignat S., Vassilev T., Stahl D.et al. Immunomodulation of autoimmunity by intravenous immunoglobulin through interaction with immune networks. Vox Sang. 83:2002;49-52.
43. Samuelsson A., Towers T.L., Ravetch J.V. Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor. Science. 291:2001;484-486.
44. Bruhns P., Samuelsson A., Pollard J.W., Ravetch J.V. Colony-stimulating factor-1-dependent macrophages are responsible for IVIG protection in antibody-induced autoimmune disease. Immunity. 18:2003;573-581.
45. Milgrom F., Humphrey L.J., Tonder O., Yasuda J., Witebsky E. Antibody-mediated hemadsorption by tumor tissues. Int. Arch Allergy Appl. Immunol. 33:1968;478-492.
46. Tonder O., Morse P.A., Humphrey L.J. Similarities of Fc receptors in human malignant tissue and normal lymphoid tissue. J. Immunol. 113:1974;1162-1169.
47. Witz I.P. Tumor-bound immunoglobulins: in situ expressions of humoral immunity. Adv. Cancer Res. 25:1977;95-148.
48. Svennevig J.L., Andersson T.R. Cells bearing Fc receptors in human malignant solid tumours. Br. J. Cancer. 45:1982;201-208.
49. Noltenius H.W. Fc and complement receptors on malignant tumor cells. Cancer. 48:1981;1761-1767.
50. Cassard L., Cohen-Solal J.F.G., Galinha A., Sastre-Garau X., Mathiot C., Galon J.et al. Modulation of tumor growth by inhibitory FcγR expressed by human melanoma cells. J. Clin. Invest. 110:2002;1549-1557.
51. Witz I.P., Ran M. FcR may function as a progression factor of nonlymphoid tumors. Immunol Res. 11:1992;283-295.
52. Basten A., Miller J.F., Sprent J., Pye J. A receptor for antibody on B lymphocytes. Part I. Method of detection and functional significance. J. Exp. Med. 135:1972;610-626.
53. Dickler H.B., Kunkel H.G. Interaction of aggregated gamma-globulin with B lymphocytes. J. Exp. Med. 136:1972;191-196.
54. Yoshida T.O., Andersson B. Evidence for a receptor recognizing antigen complexed immunoglobulin on the surface of activated mouse thymus lymphocytes. Scand J. Immunol. 1:1972;401-408.
55. Fridman W.H., Golstein P. Immunoglobulin-binding factor present on and produced by thymus-processed lymphocytes (T cells). Cell Immunol. 11:1974;442-455.